Liraglutide Mechanism of Action — Research Reference
Liraglutide is characterized as a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of compounds extensively investigated in metabolic research models. Its mechanism involves binding to and activating GLP-1 receptors, triggering intracellular signaling cascades that influence various cellular processes. These effects are of significant interest in understanding metabolic regulation and cellular function within controlled laboratory settings.
This research reference page provides an in-depth exploration of Liraglutide’s molecular and cellular interactions, drawing from numerous PubMed publications detailing its observed effects and several ClinicalTrials.gov registered studies that further contextualize its investigative utility. Researchers utilize Liraglutide to probe pathways related to glucose homeostasis, energy metabolism, and cellular protection in experimental models, contributing to a broader understanding of metabolic physiology and its potential modulators.
Liraglutide: A Synthetic GLP-1 Receptor Agonist
Liraglutide represents a well-characterized synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone. As a GLP-1 receptor agonist, its primary mechanism of action involves binding to and activating the GLP-1 receptor (GLP-1R), a G protein-coupled receptor widely expressed in various tissues. This activation initiates a cascade of intracellular signaling events that are extensively investigated across numerous metabolic research models. The development of liraglutide stemmed from efforts to overcome the rapid enzymatic degradation of native GLP-1 by dipeptidyl peptidase-4 (DPP-4), thereby enhancing its pharmacokinetic profile and extending its biological half-life. This extended half-life makes liraglutide a valuable tool for researchers aiming to study sustained GLP-1R activation in experimental systems, providing a stable platform for probing receptor biology and downstream physiological effects without the confounding variable of rapid peptide breakdown.
The classification of liraglutide as a research peptide is crucial for understanding its context within experimental science. Synthetic peptides like liraglutide are meticulously designed and manufactured to exhibit specific biological activities, often mimicking or modulating the actions of endogenous peptides. Researchers utilize these compounds to explore complex biological pathways, characterize receptor interactions, and investigate potential therapeutic mechanisms without the variability associated with endogenous hormone fluctuations. For an in-depth understanding of the broader category of these analytical tools, researchers can consult resources such as What are Research Peptides?. The consistent purity and defined activity of synthetic GLP-1 receptor agonists such as liraglutide ensure reproducible experimental outcomes, which are paramount in rigorous scientific inquiry.
From a structural perspective, liraglutide features a fatty acid moiety (palmitoyl group) attached via a glutamyl linker to Lys26 of the GLP-1 sequence, along with an Arg34Lys modification. This specific acylation is critical for its prolonged action, as it facilitates non-covalent binding to albumin in the bloodstream, thus reducing renal clearance and protecting it from DPP-4 degradation. The extended circulation time of liraglutide, typically around 13 hours in research models, allows for less frequent administration in *in vivo* studies, simplifying experimental protocols and minimizing potential stress factors on animal models. These structural modifications underscore the sophisticated molecular engineering applied to create stable and potent research tools, enabling detailed investigation into the pleiotropic effects of sustained GLP-1R activation.
The extensive documentation of liraglutide in scientific literature, with numerous PubMed publications indexed, underscores its utility as a foundational research tool. Furthermore, its involvement in several registered studies on ClinicalTrials.gov, while focused on human applications, provides researchers with a rich body of data on the observed physiological responses to GLP-1R agonism, which can inform the design and interpretation of preclinical investigations. Researchers can leverage this vast existing knowledge base to formulate hypotheses, select appropriate experimental models, and interpret their findings within the broader context of GLP-1 receptor biology. The wealth of information available on liraglutide makes it an indispensable agent for studying metabolic regulation, cellular protection, and various other physiological processes in a controlled laboratory setting.
Molecular Architecture and Receptor Binding Dynamics
The molecular architecture of liraglutide is central to its efficacy as a long-acting GLP-1 receptor agonist in research models. Liraglutide is a 31-amino acid peptide, modified from the native human GLP-1 (7-37) sequence. Key structural alterations include the substitution of Lysine at position 34 with Arginine (Arg34Lys) and, most notably, the attachment of a C16 fatty acid (palmitic acid) via a glutamic acid linker to the Lysine residue at position 26. This intricate design is critical for imparting the desired pharmacological properties. The peptide backbone ensures specific recognition and binding to the GLP-1R, while the fatty acid tail enables reversible binding to albumin in the systemic circulation. This albumin binding dramatically reduces the rate of enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and minimizes renal clearance, thereby extending the compound’s half-life and facilitating sustained receptor activation in experimental settings.
The GLP-1 receptor itself is a member of the class B family of G protein-coupled receptors (GPCRs), characterized by a relatively large N-terminal extracellular domain (ECD) and a seven-transmembrane helical bundle. The binding of GLP-1R agonists like liraglutide is a two-step process involving distinct interaction sites on the receptor. Initially, the C-terminal portion of liraglutide engages with the N-terminal ECD of the GLP-1R, a region critical for high-affinity binding and conformational stabilization. Subsequently, the N-terminal part of liraglutide interacts with the transmembrane domain of the receptor, initiating the conformational changes necessary for G protein coupling and subsequent intracellular signaling. This hierarchical binding mechanism ensures exquisite specificity and potency, allowing researchers to precisely modulate GLP-1R activity in *in vitro* and *in vivo* experimental systems.
Understanding the precise binding dynamics of liraglutide to the GLP-1R is paramount for researchers investigating receptor pharmacology. Studies employing biophysical techniques, such as surface plasmon resonance and receptor-ligand binding assays, have elucidated the kinetics of liraglutide-receptor interaction. These investigations reveal that liraglutide exhibits high affinity for the GLP-1R, comparable to native GLP-1, but with a slower dissociation rate attributed to its structural modifications and potentially its interaction with lipid bilayers in close proximity to the receptor. The prolonged residence time of liraglutide at the receptor contributes significantly to its sustained pharmacological effects, allowing for sustained activation of downstream signaling pathways over an extended period, a critical factor when designing experiments to study long-term cellular adaptations or chronic physiological responses.
Furthermore, the interaction of liraglutide with albumin and its subsequent release dynamics also play a crucial role in its overall pharmacokinetics and receptor binding. While albumin binding prolongs its circulating half-life, it also presents a dynamic equilibrium where free liraglutide is available to bind to GLP-1Rs. Research models exploring this dynamic often employ techniques to measure free vs. bound liraglutide concentrations, providing insights into its bioavailability at the target tissue level. The fatty acid moiety’s ability to intercalate into cell membranes near the receptor, potentially increasing local concentrations of the agonist, is another area of active investigation, suggesting an additional layer of complexity in its binding and activation profile that contributes to its unique research utility compared to other GLP-1R agonists.
Intracellular Signaling Cascades Activated by Liraglutide
The activation of the GLP-1 receptor by liraglutide initiates a complex and multifaceted array of intracellular signaling cascades, predominantly mediated through the classical Gs-protein/adenylyl cyclase/cAMP pathway. Upon liraglutide binding, the GLP-1R undergoes a conformational change that promotes the exchange of GDP for GTP on the alpha subunit of the coupled Gs protein. This activated Gs-alpha subunit then stimulates adenylyl cyclase, leading to a rapid increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP, in turn, activates protein kinase A (PKA), a serine/threonine kinase that phosphorylates numerous downstream targets, including ion channels, transcription factors, and enzymes involved in metabolism. This canonical pathway is fundamental to many of liraglutide’s well-described effects, such as glucose-dependent insulin secretion in pancreatic beta-cells and various cytoprotective actions observed in experimental models.
Beyond the PKA pathway, liraglutide’s activation of the GLP-1R also engages other important signaling molecules, contributing to its diverse biological impact. The exchange protein directly activated by cAMP (Epac) represents a PKA-independent cAMP effector that is increasingly recognized for its role in GLP-1R signaling. Epac activation, particularly Epac2 in pancreatic beta-cells, contributes to insulin secretion by mobilizing intracellular calcium stores and modulating ion channel activity. Researchers investigating the nuances of GLP-1R agonism often differentiate between PKA-dependent and Epac-dependent pathways to dissect the precise mechanisms underlying specific cellular responses. This allows for a deeper understanding of how liraglutide can orchestrate a broad spectrum of cellular events, from acute secretory responses to more prolonged transcriptional changes, in various research models.
Furthermore, accumulating evidence suggests that liraglutide’s interaction with the GLP-1R can also activate Gq-protein coupled pathways, leading to the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which subsequently mobilize intracellular calcium and activate protein kinase C (PKC). While less prominent than the Gs/cAMP pathway, Gq coupling may contribute to certain effects, particularly in non-pancreatic tissues or under specific physiological conditions. Additionally, GLP-1R activation has been shown to modulate mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK. These pathways are crucial for cell growth, differentiation, and stress responses, indicating liraglutide’s potential involvement in cellular plasticity and survival mechanisms observed in various experimental models of cellular injury or metabolic stress.
The interplay between these diverse signaling cascades allows liraglutide to exert pleiotropic effects, ranging from acute metabolic modulation to long-term cytoprotection and gene expression regulation. For instance, in models of cardiovascular disease, liraglutide’s effects on endothelial function and cardiomyocyte survival may involve a coordinated activation of cAMP/PKA, PI3K/Akt, and MAPK pathways, all contributing to anti-apoptotic and anti-inflammatory responses. Researchers conducting *in vitro* studies often employ specific inhibitors or genetic knockdowns of key signaling molecules to precisely map the contribution of each pathway to observed outcomes, offering a granular understanding of how liraglutide’s molecular interactions translate into complex cellular behaviors. This detailed understanding of intracellular signaling is paramount for fully appreciating the mechanisms by which liraglutide influences cellular physiology in a research context.
Modulation of Pancreatic Islet Function in Research Models
The pancreatic islets, particularly the beta-cells, are primary targets for GLP-1 receptor agonists like liraglutide, and their functional modulation is a cornerstone of research into its metabolic effects. In various *in vitro* and *in vivo* research models, liraglutide has been consistently shown to enhance glucose-dependent insulin secretion from beta-cells. This effect is not merely an increase in basal insulin release but a potentiation of insulin secretion specifically in response to elevated glucose levels, thereby minimizing the risk of hypoglycemia in experimental settings when glucose is low. The mechanism involves the activation of the GLP-1 receptor, leading to increased intracellular cAMP and subsequent activation of PKA and Epac2, which collectively amplify the glucose-sensing machinery of the beta-cell, promote closure of ATP-sensitive potassium channels, and facilitate calcium influx, ultimately triggering insulin granule exocytosis.
Beyond acute insulinotropic effects, liraglutide also exerts profound influences on beta-cell mass and survival in chronic research models. Studies using rodent models of metabolic dysfunction and isolated human islet cultures have demonstrated that liraglutide can promote beta-cell proliferation, inhibit apoptosis, and enhance cellular differentiation. The anti-apoptotic effects are often linked to the activation of the PI3K/Akt signaling pathway, which is downstream of GLP-1R activation and leads to the phosphorylation and inactivation of pro-apoptotic proteins. By preserving and potentially expanding functional beta-cell mass, liraglutide offers a valuable avenue for researchers investigating strategies to counteract beta-cell decline, a hallmark in models of glucose dysregulation. This sustained action on beta-cell health distinguishes long-acting GLP-1R agonists in the realm of experimental metabolic research.
Liraglutide’s influence extends beyond beta-cells to the alpha-cells within the pancreatic islets, where it plays a critical role in glucagon regulation. Research in both animal and human islet models has shown that liraglutide effectively suppresses inappropriate glucagon secretion, particularly in hyperglycemic conditions. This suppression is glucose-dependent; while glucagon secretion is inhibited when glucose levels are high, it is not significantly affected when glucose levels are low, again minimizing the risk of inducing hypoglycemia. The mechanism for glucagon suppression is multifaceted, involving both direct GLP-1R signaling on alpha-cells and indirect effects mediated by paracrine signaling from adjacent beta-cells (e.g., via insulin or somatostatin). This dual action on insulin and glucagon secretion contributes significantly to the overall glucose-lowering effects observed in metabolic research models.
Furthermore, liraglutide has been investigated for its potential to improve overall islet architecture and reduce inflammation within the pancreatic islets in various stress models. Chronic exposure to metabolic stressors, such as high-fat diets or specific cytokines, can lead to islet inflammation and dysfunction. Experimental studies have indicated that liraglutide may mitigate these inflammatory responses, characterized by reduced infiltration of immune cells and lower expression of pro-inflammatory cytokines, contributing to improved islet integrity and function. This anti-inflammatory aspect positions liraglutide as a significant tool for researchers exploring immunometabolism and the interplay between inflammation and metabolic health, particularly in the context of progressive pancreatic dysfunction in animal models.
Extra-Pancreatic Target Tissues and Systemic Effects in Experimental Systems
While the pancreatic islets are primary targets, the GLP-1 receptor is widely distributed throughout numerous extra-pancreatic tissues, allowing liraglutide to exert a broad spectrum of systemic effects investigated across diverse experimental systems. The central nervous system (CNS) is a prominent extra-pancreatic target, with GLP-1Rs found in various brain regions including the hypothalamus, brainstem, and hippocampus. In research models, liraglutide has been shown to cross the blood-brain barrier, albeit in limited quantities, and exert effects on appetite regulation, food intake, and satiety. Studies in rodents have demonstrated that intracerebroventricular administration or chronic systemic treatment with liraglutide can reduce body weight gain and decrease food consumption, suggesting its involvement in neural circuits governing energy homeostasis. These findings open avenues for investigating brain-gut axis interactions and the neuropathology of metabolic disorders.
Beyond appetite regulation, GLP-1R activation by liraglutide in the brain has been implicated in neuroprotection and cognitive function in various preclinical models. Research using models of neurodegenerative diseases, such as Alzheimer’s or Parkinson’s, has suggested that liraglutide may reduce neuronal inflammation, inhibit amyloid-beta plaque formation, and improve synaptic plasticity and memory deficits. The mechanisms proposed include enhanced neuronal survival through activation of the PI3K/Akt pathway, reduction of oxidative stress, and modulation of glial cell activity. These intriguing findings highlight liraglutide’s potential as a research probe in neuroscience, prompting deeper investigations into its capacity to influence brain health and disease pathogenesis beyond its metabolic attributes.
The cardiovascular system also harbors GLP-1 receptors, and liraglutide’s effects in this domain are a significant area of research. Studies in animal models of cardiovascular disease have indicated that liraglutide can improve endothelial function, reduce atherosclerosis progression, and confer cardioprotective effects during ischemia-reperfusion injury. These beneficial outcomes are often attributed to direct actions on GLP-1Rs in endothelial cells, cardiomyocytes, and vascular smooth muscle, leading to increased nitric oxide production, reduced oxidative stress, and inhibition of inflammatory pathways. Furthermore, liraglutide has been observed to influence blood pressure and heart rate in experimental systems, suggesting a complex interplay of direct vascular effects and indirect systemic influences on cardiac performance.
Other extra-pancreatic tissues demonstrating GLP-1R expression and responsiveness to liraglutide include the gastrointestinal tract, kidneys, adipose tissue, and skeletal muscle. In the gut, liraglutide slows gastric emptying, which contributes to its effects on satiety and postprandial glucose regulation in research models. Renal GLP-1Rs have been implicated in effects on natriuresis and renal protection in models of kidney disease, while in adipose tissue and skeletal muscle, liraglutide may influence glucose uptake, lipolysis, and energy expenditure. The systemic integration of these multi-tissue effects culminates in the observed improvements in whole-body metabolic homeostasis in diverse preclinical models, making liraglutide a valuable tool for understanding complex physiological systems beyond single-organ biology.
Investigating Liraglutide’s Influence on Cellular Metabolism and Bioenergetics
Liraglutide, as a GLP-1 receptor agonist, significantly influences cellular metabolism and bioenergetics across various cell types and tissues, a phenomenon extensively investigated in research models. At a fundamental level, the activation of GLP-1R by liraglutide triggers cascades that modulate glucose and lipid utilization pathways. In pancreatic beta-cells, as previously discussed, this leads to glucose-dependent insulin secretion, but its metabolic influence extends to extra-pancreatic tissues. For instance, in hepatic cells, liraglutide has been shown in some *in vitro* and *in vivo* studies to reduce hepatic glucose production and improve insulin sensitivity, potentially by altering key enzymatic activities in gluconeogenesis and glycogenolysis, and by influencing the expression of genes involved in glucose metabolism. This suggests a role in hepatic metabolic reprogramming.
Beyond glucose metabolism, liraglutide exerts significant effects on lipid metabolism. Research in adipocytes and hepatocytes has indicated that liraglutide can influence lipogenesis, lipolysis, and fatty acid oxidation. Studies have shown that GLP-1R activation can lead to a reduction in triglyceride synthesis and an increase in fatty acid oxidation, processes crucial for energy homeostasis. These effects are often mediated through downstream signaling pathways that alter the activity of key enzymes like Acetyl-CoA Carboxylase (ACC) and Carnitine Palmitoyltransferase I (CPT1), as well as transcription factors such as SREBP-1c and PPAR-alpha. Understanding these lipid-modulating effects is critical for researchers investigating metabolic disorders characterized by dyslipidemia and ectopic fat accumulation.
Mitochondrial function, the powerhouse of the cell, is another significant area where liraglutide’s influence on bioenergetics is explored. In various cellular models, including cardiomyocytes, neurons, and pancreatic beta-cells, GLP-1R activation by liraglutide has been associated with improved mitochondrial respiration, enhanced ATP production, and increased mitochondrial biogenesis. These effects are thought to contribute to cellular resilience and protection against metabolic stress. For example, in models of oxidative stress or nutrient overload, liraglutide has been observed to preserve mitochondrial integrity, reduce the generation of reactive oxygen species (ROS), and improve the efficiency of the electron transport chain. Investigating these mitochondrial adaptations provides crucial insights into the cytoprotective mechanisms of liraglutide.
The systemic impact of these cellular metabolic shifts manifests in altered whole-body energy balance in experimental animal models. Beyond reduced food intake, liraglutide has been investigated for its potential to increase energy expenditure, possibly through direct or indirect effects on thermogenesis and brown adipose tissue activity. While direct mechanisms are still under investigation, the cumulative effects on glucose homeostasis, lipid metabolism, and mitochondrial efficiency contribute to the broader metabolic improvements observed in models of obesity and insulin resistance. Researchers utilize liraglutide as a tool to dissect these complex metabolic pathways, employing techniques such as Seahorse Bioscience assays for measuring cellular respiration, stable isotope tracing for metabolic flux analysis, and quantitative proteomics to identify modulated proteins.
Exploring Liraglutide’s Role in Cellular Protection and Stress Responses
Liraglutide’s actions extend beyond direct metabolic modulation to encompass significant roles in cellular protection and the attenuation of various stress responses, a critical area of investigation in cellular aging and disease models. One prominent aspect is its anti-apoptotic effects, observed across diverse cell types including pancreatic beta-cells, neurons, and cardiomyocytes. In models of induced cellular injury, such as glucolipotoxicity, oxidative stress, or inflammatory challenge, liraglutide has been shown to reduce programmed cell death. This is often attributed to the activation of prosurvival signaling pathways, particularly the PI3K/Akt pathway, which phosphorylates and inactivates pro-apoptotic proteins like Bad, thereby inhibiting mitochondrial-mediated apoptosis. Researchers often employ caspase activity assays, TUNEL staining, and Western blotting for apoptotic markers (e.g., cleaved caspase-3, PARP) to quantify these protective effects.
The anti-inflammatory properties of liraglutide constitute another key aspect of its cellular protection profile. Chronic low-grade inflammation is a pervasive feature of many metabolic and age-related diseases. In various *in vitro* and *in vivo* research models, liraglutide has been demonstrated to attenuate inflammatory responses by reducing the expression and secretion of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-1beta) and chemokines from immune cells and parenchymal cells. This anti-inflammatory action may be mediated through the modulation of nuclear factor kappa B (NF-κB) signaling and other inflammatory pathways, contributing to improved cellular function and tissue integrity in stressed environments. These findings position liraglutide as a valuable research agent for exploring the intricate links between metabolism, inflammation, and cellular resilience.
Liraglutide also exhibits antioxidant properties, which contribute to its overall cytoprotective effects. Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, can lead to significant cellular damage. Research in various cell lines and animal models suggests that liraglutide can reduce oxidative stress by enhancing the activity of endogenous antioxidant enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) and by directly scavenging ROS. This reduction in oxidative burden helps to preserve mitochondrial function, protect cellular macromolecules from damage, and maintain cellular homeostasis under challenging conditions. Investigators frequently utilize assays for ROS levels (e.g., DCFH-DA), lipid peroxidation products (e.g., MDA), and antioxidant enzyme activities to assess these effects.
Furthermore, liraglutide has been implicated in modulating endoplasmic reticulum (ER) stress, another critical cellular stress response pathway that, when prolonged, can lead to cell dysfunction and apoptosis. In models of metabolic overload or drug-induced ER stress, liraglutide has been shown to mitigate aspects of the unfolded protein response (UPR), helping cells to restore ER homeostasis. This modulation of ER stress contributes to the maintenance of protein folding capacity and overall cellular viability. The multifaceted nature of liraglutide’s protective mechanisms against apoptosis, inflammation, oxidative stress, and ER stress underscores its utility as a powerful tool for researchers studying cellular resilience and investigating therapeutic strategies for various chronic diseases and age-related cellular decline.
Research Applications and Emerging Areas of Investigation with Liraglutide
Liraglutide’s well-defined mechanism as a GLP-1 receptor agonist and its favorable pharmacokinetic profile have cemented its status as a cornerstone research tool in metabolic science. Its primary application in research models continues to be the elucidation of pancreatic beta-cell physiology, focusing on glucose-dependent insulin secretion, beta-cell proliferation, and survival in the context of various models of glucose dysregulation. Beyond these core areas, liraglutide is extensively utilized to investigate systemic metabolic improvements, including effects on hepatic glucose production, lipid metabolism, and overall energy balance in animal models
Frequently Asked Questions
What is Liraglutide’s primary mechanism of action in research models?
Liraglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, activating GLP-1 receptors to initiate various intracellular signaling pathways within studied cellular and physiological systems.
To what class of compounds does Liraglutide belong?
Liraglutide is classified as a GLP-1 receptor agonist, a synthetic analog designed to mimic the actions of native GLP-1.
How does Liraglutide typically activate GLP-1 receptors at the molecular level?
Liraglutide binds to the extracellular domain of the GLP-1 receptor, a G protein-coupled receptor (GPCR), inducing conformational changes that lead to the activation of intracellular G proteins and subsequent downstream signaling.
What are some key intracellular signaling pathways influenced by Liraglutide?
Activation of the GLP-1 receptor by Liraglutide primarily stimulates adenylate cyclase, leading to increased cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac).
Which cell types are commonly investigated as targets for Liraglutide’s effects in research?
Pancreatic beta cells are primary targets, where Liraglutide influences insulin secretion, cell proliferation, and apoptosis in research models. Alpha cells are also studied for glucagon suppression, along with peripheral tissues like adipose, muscle, liver, and neuronal cells.
Does Liraglutide exhibit effects beyond the pancreas in experimental systems?
Yes, research indicates that Liraglutide can influence metabolism in extra-pancreatic tissues, including adipose tissue (lipolysis), skeletal muscle (glucose uptake), liver (glucose production), and central nervous system (appetite regulation, neuroprotection) within specific research contexts.
How is Liraglutide relevant to cellular aging research models?
Researchers investigate Liraglutide for its potential modulatory effects on pathways associated with cellular aging, such as oxidative stress, inflammation, mitochondrial dysfunction, and autophagy, seeking to understand its impact on cellular resilience and longevity phenotypes in in vitro and in vivo models.
What are some important considerations when studying Liraglutide’s effects in in vitro models?
Critical considerations include maintaining physiological relevance of cell lines or primary cultures, controlling for confounding factors in the experimental environment, ensuring appropriate compound concentration and exposure duration, and utilizing robust assays to accurately measure cellular responses and signaling pathway activation.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.